INMUNE BIO, INC.
La Jolla, CA · Founded 2015 · CIK 0001711754 · Biotech · Public
XPro1595, a dominant-negative TNF inhibitor molecule for treatment-resistant depression
inmunebio.com →- Grants
- $2.0M
- 2 awards
- Sector median: 1
- Raised
- $8.0M
- 2 Form D · May 2019
- 89 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 17
- 0 granted · 17 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $3,340,000 | |
| Private capital raised | Form D · SEC | $4,699,904 | |
| Federal grant | Department of Health and Human Services · Phase II · Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-related Deficits in Reward Circuitry and Motivation in Depression | $739,739 | |
| Federal grant | Department of Health and Human Services · Phase II · Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-related Deficits in Reward Circuitry and Motivation in Depression | $1,210,682 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2316 | Moleculin Biotech, Inc. | — | $6.0M |
| 2317 | ProtoKinetix, Inc. | — | $3.8M |
| 2318 | CERO THERAPEUTICS HOLDINGS, INC. | — | $16M |
| 2319 | INMUNE BIO, INC. | — | $8.0M |
| 2320 | ARUKA BIO, INC. | — | $3.6M |
| 2321 | Genomics PLC | — | — |
| 2322 | Lennham Pharmaceuticals, Inc. | — | $3.5M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- J. GanjeiDirector
- Scott JudaDirector
- Terry KnappDirector
- Mark LowdellDirector · Executive Officer
- David MossDirector · Executive Officer
- Timothy SchroederDirector
- David SzymkowskiDirector
- Raymond TesiDirector · Executive Officer
Patents
- Method For Detecting Anti-drug Antibodies Against Self-assembling Trimeric Biologics Using An Affinity Capture Elution-protein A/g Assayapplication
- Human T-cell Acute Lymphoblastic Leukemia Cell Line & Applications For Treating Cancerapplication
- Treatment Of Non-alcoholic Steatohepatitisapplication
- Compositions & Method Of Treating Epilepsy By Selective Sequestration Of Soluble Tnfapplication
- Stable Bioconjugates Of Soluble Tnf Muteinsapplication
- Bioconjugates Of Dominant Negative Tnfapplication
- COMPOSITIONS COMPRISING POOLED hucMSCs FOR THERAPEUTIC USESapplication
- Human T-cell Acute Lymphoblastic Leukemia Cell Line & Applications For Treating Cancerapplication
- Compositions Comprising Dominant Negative Tnf Protein And Methods For Therapeutic Deliveryapplication
- Biomarker Driven Methods For Treating Major Depressive Disorderapplication
- Method For Treating Therapy-resistant MUC4+ Cancerapplication
- Treatment Of Non-alcoholic Steatohepatitisapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.